TY  - JOUR
  - Schellekens H, McNamara O, Dinan TG, McCarthy JV, McGlacken GP, Cryan JF
  - 2013
  - April
  - The Journal of pharmacy and pharmacology
  - Semagacestat, a ¿-secretase inhibitor, activates the growth hormone secretagogue (GHS-R1a) receptor.
  - Validated
  - ()
  - 65
  - 4
  - 528
  - 538
  - Semagacestat, is a ¿-secretase inhibitor, which belongs to a class of drugs that are being developed as therapeutic agents for Alzheimer's disease (AD). This study aims to evaluate another potential effect of semagacestat, namely its ability to stimulate the growth hormone secretagogue receptor (GHS-R1a), which may also contribute to its therapeutic efficacy.
  - 10.1111/jphp.12010
DA  - 2013/04
ER  - 

@article{V281056198,
   = {Schellekens H,  McNamara O and  Dinan TG,  McCarthy JV and  McGlacken GP,  Cryan JF },
   = {2013},
   = {April},
   = {The Journal of pharmacy and pharmacology},
   = {Semagacestat, a ¿-secretase inhibitor, activates the growth hormone secretagogue (GHS-R1a) receptor.},
   = {Validated},
   = {()},
   = {65},
   = {4},
  pages = {528--538},
   = {{Semagacestat, is a ¿-secretase inhibitor, which belongs to a class of drugs that are being developed as therapeutic agents for Alzheimer's disease (AD). This study aims to evaluate another potential effect of semagacestat, namely its ability to stimulate the growth hormone secretagogue receptor (GHS-R1a), which may also contribute to its therapeutic efficacy.}},
   = {10.1111/jphp.12010},
  source = {IRIS}
}